Increasing Prevalence Of Cardiovascular Diseases Fueling The Growth Of The Market Due To Rising Risk Factors And Mortality Rates Emerges as a Core Driver of the Ticagrelor Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Ticagrelor Market Through 2025?
The market for ticagrelor has seen consistent growth in recent years, with projections suggesting it will rise from $1.79 billion in 2024 to $1.93 billion in 2025, this suggests a compound annual growth rate (CAGR) of 7.6%. The escalation observed in the historical period can be credited to factors such as an increased occurrence of cardiovascular diseases, a surge in the aging population, heightening awareness about cardiac health, progress in pharmaceutical research, and an upward trend in the incidence of acute coronary syndrome.

What's the Projected Size of the Global Ticagrelor Market by 2029?
The market for ticagrelor is predicted to experience notable expansion in the following years, swelling to $2.57 billion in 2029, with a compound annual growth rate (CAGR) of 7.4%. The surge over the predicted period is resulting from the increased uptake of personalized medicine, expanded healthcare spending, a growing need for less intrusive treatments, a heightened emphasis on preventive cardiology, and government-led actions for heart care. The anticipated trends for this period encompass the emergence of personalized medicine, the debut of generic ticagrelor, the incorporation of artificial intelligence into drug discovery, the creation of next-generation antiplatelet drugs, and an emphasis on patient adherence with fixed-dose combinations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ticagrelor-global-market-report

Top Growth Drivers in the Ticagrelor Industry: What's Accelerating the Market?
The ticagrelor market's growth is anticipated to be fueled by the rising prevalence of cardiovascular diseases. These diseases, which include coronary heart disease, heart failure, stroke, and hypertension, are disorders that affect the heart and blood vessels. The growth in the prevalence of these diseases is primarily due to unhealthy diet habits, such as excessive intake of saturated fats, trans fats, added sugars, and sodium, which can lead to high blood pressure, obesity, and high cholesterol levels - significant risk factors for heart-related conditions. Ticagrelor contributes to the treatment of cardiovascular diseases by inhibiting platelet aggregation and lowering the risk of blood clot formation. It enhances patient outcomes by reducing the probability of heart attacks and strokes, particularly in people at high risk. For instance, the American Heart Association, a nonprofit organization based in the US, stated in January 2024 that the age-adjusted death rate due to cardiovascular diseases increased to 233.3 per 100,000 in 2022, which is a 4.0% increase from 224.4 per 100,000 in 2021. Thus, the rising prevalence of cardiovascular diseases is fuelling the expansion of the ticagrelor market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24726&type=smp

What Trends Will Shape the Ticagrelor Market Through 2029 and Beyond?
Key players in the ticagrelor industry are prioritizing the attainment of official certifications from governmental bodies for the growth of product indications, enhancing their market presence and bolstering their competitive edge. This approval from regulatory bodies guarantees that the product being marketed and sold adheres to the stipulated safety, efficiency, and quality standards. For example, in May 2025, Alembic Pharmaceuticals Ltd., a medicinal organization based in India, was granted an abbreviated new drug application (ANDA) by the US Food & Drug Administration (USFDA) for their generic ticagrelor 90mg tablets, and also received conditional approval for the 60mg variant. These tablets serve to mitigate cardiovascular risks through the inhibition of platelet aggregation, thus stopping the emergence of blood clots.

What Are the Main Segments in the Ticagrelor Market?
The ticagrelor market covered in this report is segmented -

1) By Type: 90 mg Tablet, 60 mg Tablet
2) By Drug Class: Antiplatelet Agents, Antithrombotic Agents
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Acute Coronary Syndrome, Myocardial Infarction, Stroke Prevention, Other Applications
5) By End User: Hospitals And Clinics, Ambulatory Centers, Other End Users

Subsegments:
1) By 90 Mg Tablet: Standard 90 Mg Ticagrelor Tablet, Extended-Release 90 Mg Ticagrelor Tablet
2) By 60 Mg Tablet: Standard 60 Mg Ticagrelor Tablet, Extended-Release 60 Mg Ticagrelor Tablet

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24726&type=smp

Which Top Companies are Driving Growth in the Ticagrelor Market?
Major companies operating in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., PhaseBio Pharmaceuticals Inc.

Which Regions Will Dominate the Ticagrelor Market Through 2029?
North America was the largest region in the ticagrelor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ticagrelor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24726

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.